Autres langues Centessa Pharmaceuticals plc

Actions

CNTA

US1523091007

Temps réel estimé Cboe BZX Autres places de cotation 20:15:52 20/05/2024			Varia. 5j.	Varia. 1 janv.
9,015 ^USD	+1,63 %		+1,70 %	+12,81 %

13/05	Centessa Pharmaceuticals plc annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
24/04	Les fonds négociés en bourse sont en hausse, les contrats à terme sur actions sont mitigés avant la cloche de mercredi, dans un contexte de déluge de résultats.	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024	13/05
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	24/04
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	24/04
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares	24/04
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering	24/04
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares	23/04
Centessa Pharmaceuticals Announces Open IND for ORX750, Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	23/04
Centessa Pharmaceutical Gets FDA's Approval to Begin Phase 1 Trial of Narcolepsy Drug Candidate	22/04
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	22/04
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	22/04
Centessa Pharmaceuticals plc Announces Open IND for ORX750	22/04
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023	28/03
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing	26/03
Centessa Pharmaceuticals : March Corporate Overview	05/03
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference	22/02
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)	09/02
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies	08/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Centessa Pharmaceuticals plc

Actions

CNTA

US1523091007

Autres langues

Filtres